Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, … Read more
Mineralys Therapeutics, Inc. Common Stock (MLYS) - Total Assets
Latest total assets as of September 2025: $599.95 Million USD
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) holds total assets worth $599.95 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mineralys Therapeutics, Inc. Common Stock - Total Assets Trend (2020–2024)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mineralys Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Mineralys Therapeutics, Inc. Common Stock's total assets of $599.95 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mineralys Therapeutics, Inc. Common Stock's current assets represent 99.7% of total assets in 2024, an increase from 98.7% in 2020.
- Cash Position: Cash and equivalents constituted 55.4% of total assets in 2024, down from 94.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Mineralys Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Mineralys Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Mineralys Therapeutics, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Mineralys Therapeutics, Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Mineralys Therapeutics, Inc. Common Stock is currently not profitable relative to its asset base.
Mineralys Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 25.50 | 8.55 | 2.20 |
| Quick Ratio | 25.50 | 8.55 | 2.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $576.28 Million | $ 236.41 Million | $ 6.07 Million |
Mineralys Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Mineralys Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.74 |
| Latest Market Cap to Assets Ratio | 6.65 |
| Asset Growth Rate (YoY) | -18.2% |
| Total Assets | $205.90 Million |
| Market Capitalization | $1.37 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Mineralys Therapeutics, Inc. Common Stock's assets at a significant premium ( 6.65x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Mineralys Therapeutics, Inc. Common Stock's assets decreased by 18.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mineralys Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total assets of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $205.90 Million | -18.17% |
| 2023-12-31 | $251.64 Million | +119.88% |
| 2022-12-31 | $114.44 Million | +928.69% |
| 2021-12-31 | $11.12 Million | +648.65% |
| 2020-12-31 | $1.49 Million | -- |